Around 800 people will be eligible for treatment with Kadcyla
News
AbbVie completes acquisition of Allergan
The move significantly expands and diversifies AbbVie’s revenue base
PM faces calls for inquiry into BAME COVID-19 death risk
Campaigners are urging the government to investigate the higher death risk from coronavirus for people with black, Asian and minority ethnic (BAME) backgrounds
Merck names Doina Ionescu as UK and Ireland general manager
Dr Mike England joins as medical director for UK & ROI
Imperial College London partners with NHS Trust to make PPE
More than 6,000 visors have already been delivered to Charing Cross Hospital
Rebiotix, Ferring’s microbiome-based therapy RBX2660 shows promise
RBX2660 may bring an innovative therapeutic option to patients suffering from C. diff
Speedy US approval for Novartis’ Tabrecta
The approval gives NSCLC patients whose tumours carry the MET exon 14 skipping mutation a new treatment option
Aberdeen Uni proceeds with COVID-19 mass screening research
The Scottish government has given funds £101,903 to support the project
US regulators permit AbbVie/Allergan merger
The closing of the acquisition remains subject to other customary closing conditions
NICE publishes rapid COVID-19 guideline for acute kidney injury
The guideline is designed to help healthcare professionals who are not kidney specialists to prevent, detect and manage AKI in hospitalised patients with suspected or confirmed COVID-19
US OK’s AZ’ Farxiga for heart failure with reduced ejection fraction
Farxiga is the first sodium glucose co-transporter 2 inhibitor cleared by the FDA to treat heart failure with reduced ejection fraction
ICR welcomes new advanced prostate cancer treatment guideline
NHS England has expanded access to targeted hormone therapies for advanced prostate cancer
Menarini to buy Stemline for up to $677 million
The move will establish Menarini’s presence in the US biopharma market
Newron drops development of sarizotan in Rett syndrome
The experimental 5-HT1A receptor agonist and D2 receptor antagonist was not effective on primary or secondary endpoints
Sanofi/Regeneron’s Libtayo shows benefit in BCC
BCC marks the second non-melanoma skin cancer for which Libtayo has demonstrated first-in-class data, the firms note
